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Methods: Healthy adults aged 18—60 years (n = 313) and
elderly aged >60 years (n = 173) received two injections
(1:1 ratio), 3 weeks apart, and a six-month booster dose,
of a subunit MF59-adjuvanted H5N1 (A/Vietnam/1194/2004)
inﬂuenza (clade 1) vaccine containing either 7.5g or 15g
hemagglutinin. All participants were followed for safety
assessments. Blood samples were taken before each vac-
cination, and again three weeks and six months after each
vaccination. Serum H5N1 antibody titres were assessed by
single radial hemolysis and microneutralisation assays.
Findings: Mild pain at the injection site was the most
common reaction overall and decreased with subsequent
dosing. The humoral immune response to 7.5g vaccine was
non-inferior to that of 15g. Seroprotection rates after the
second vaccination ranged from 80% to 86% as measured
by SRH and 76% to 85% as measured by MN assays across
vaccine dose and age strata. After the six-month booster,
seroprotection rates, as measured by SRH, increased in
adults and elderly in the 7.5g group from 19% and 22%
at baseline (pre-booster) to 90% and 84%, respectively,
three weeks later, and in the 15g group from 25% and
64% at baseline for adults and elderly, respectively, to
91% and 88%. Heterologous immune response against the
A/H5N1/turkey/Turkey/05 strain was detectable after the
second vaccination and the booster vaccination, with sero-
protection rate of 57—76% and 78—88% after the second and
third dose respectively.
Interpretations: Both formulations were well tolerated
and equivalent. The 7.5g met all three SRH criteria for
pandemic vaccines licensure in the EU in both adult and
elderly participants. The cross-clade immune response sug-
gests that this vaccine adjuvanted with MF 59 is appropriate
for H5N1 prepandemic vaccination programs.
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Background: Universal varicella vaccination was intro-
duced as a public health initiative in Australia in November
2005, but there are no reported vaccine effectiveness stud-
ies in Australia carried out since commencement of this
programme. An outbreak of varicella infection occurred in
a childcare centre (CCC) in Sydney, Australia in Septem-
ber 2006. We used this outbreak to assess varicella vaccine
effectiveness.
Methods: Self-administered questionnaires were used to
obtain vaccination status and medical history from parents
of all children at the CCC. The parents of all children with
varicella infection were then contacted by telephone to
obtain information regarding disease severity. Children aged
<12 months or who had varicella infection prior to the out-
break were excluded. Vaccine effectiveness was calculated
using the cohort method.
Results: 112 children attended the CCC at the time of
the outbreak; 86 questionnaires were returned (response
rate 77%). Ten children were excluded from the study due to
age or previous varicella infection. 54% (41/76) of suscepti-
ble children were vaccinated at the time of the outbreak.
There were 23 cases of varicella infection (attack rate 30%);
of these, 8 (35%) had previously received the varicella vac-
cine. All cases hadmild-moderate disease. The attack rate in
the vaccinated population was 20% (8/41) compared to 43%
(15/35) in the unvaccinated population. Vaccine efﬁcacy in
this outbreak was 54%. The relative risk (RR) of mild disease
in the unvaccinated compared to the vaccinated population
was 0.94, whereas the RR of moderate to severe disease was
11.7.
Conclusion: In this outbreak, varicella vaccine did not
appear to be effective in preventing an outbreak; however
it did have a likely impact on disease severity, appar-
ently effective in preventing moderate to severe disease.
Vaccination of vulnerable populations, including catch-
up of previously missed individuals, should be strongly
encouraged to reduce severity of disease during future out-
breaks.
doi:10.1016/j.ijid.2008.05.359
19.013
Safety, Viremia and Immunogenicity of Sanoﬁ Pasteur
Tetravalent Dengue Vaccine in Adults Previously Exposed
to Live, Attenuated Flaviviruses
M. Qiao1, D. Shaw1, R. Forrat2, A. Wartel-Tram2,∗, J. Lang3
1 CMAX, Institute of Drug Technology, Adelaide, Australia
2 Sanoﬁ Pasteur, Lyon, France
3 Sanoﬁ Pasteur, Ho Chi Minh City, Vietnam
Background: Dengue disease is a major public health
problem in tropical and subtropical areas. As any of the
four serotypes of dengue virus can cause the classic or
severe hemorrhagic forms of the disease, a tetravalent
dengue vaccine is needed. Prior exposure to a ﬂavivirus
could potentially modulate the safety and immunogenicity
of a tetravalent dengue vaccine.
Methods: This open, monocenter study in Australia inves-
tigated the effect of prior exposure to live-attenuated
ﬂavivirus vaccines on the safety, viremia and immunogenic-
ity of a recombinant, live attenuated tetravalent dengue
vaccine (TDV). TDV was given to subjects who were either:
ﬂavivirus na¨ıve, or had been randomized and vaccinated 1
year previously with yellow fever vaccine (YFV) or one of
two monovalent (serotype 1 or 2) live attenuated dengue
vaccines (MDV). Exposure to MDV was hypothesized to mim-
ick natural exposure. Adverse events, biological safety, and
dengue vaccine virus viremia (qRT-PCR) were assessed to
Day28. Neutralizing antibody levels against parental viruses
were assessed on D0 and 28 by PRNT50 assay. Subjects were
healthy adults aged 18—40.
Results: 35 subjects were enrolled and received TDV: 12
were ﬂavivus-na¨ıve, 8 had received YFV, 15 had received
MDV. Clinical or biological adverse reactions after TDV were
not more frequent or more severe among those previously
vaccinated with MDV or YFV, than among na¨ıve subjects. Vac-
cine virus viremia, predominantly serotype 4, was detected
on day 14 or 21 in 47% of MDV subjects, versus 88% of YF
subjects and 83% of na¨ıve subjects. After TDV vaccination,
